WELCOME TO
MESTAG THERAPEUTICS

Transforming the lives of patients with inflammatory disease and cancer.

FIBROBLASTS. REIMAGINED.

Mestag Therapeutics was founded in 2020 by leading scientists, drug developers and investors to pioneer new medicines for people affected by inflammatory disease and cancer.

Our approach builds on recent data which points to resident cells called fibroblasts as playing a key role in driving disease. Mestag’s mission is to lead this emerging field in developing impactful precision medicines for patients through our understanding of activated fibroblast populations and their influence on immune effector cells.

Our company was created by global thought-leaders in fibroblast biology, is supported by experienced international investors and is powered by our team of scientists based in Cambridge, UK.

FIBROBLASTS. REIMAGINED.

OUR INVESTORS

Mestag is backed by leading global life sciences & healthcare investors, SV Health Investors, Johnson & Johnson Innovation – JJDC, Inc, Forbion, GV (formerly Google Ventures) and Northpond Ventures.